Symptom Assessment for GERD Patients Receiving H. Pylori Eradication
|ClinicalTrials.gov Identifier: NCT01249482|
Recruitment Status : Unknown
Verified November 2010 by National Taiwan University Hospital.
Recruitment status was: Recruiting
First Posted : November 29, 2010
Last Update Posted : December 13, 2010
|Condition or disease|
|Gastroesophageal Reflux Disease|
|Study Type :||Observational|
|Estimated Enrollment :||300 participants|
|Observational Model:||Case Control|
|Official Title:||Symptom Assessment for Patients With Gastro-esophageal Reflux Disease Receiving Helicobacter Pylori Eradication|
|Study Start Date :||September 2010|
|Estimated Study Completion Date :||August 2012|
Group B (n=100) will be given rabeprazole 20 mg qd for 8 weeks and discontinued for 2 weeks. Then, H. pylori eradication with triple therapy will be given for one week, followed by rabeprazole 20 mg qd for 7 weeks.
For patients with negative H. pylori infection (n=100), proton-pump inhibitor with rabeprazole 20 mg qd will be given for 8 weeks and discontinued.
Group A (n=100) will be given initial H. pylori eradication with triple therapy for one week, followed by proton-pump inhibitor with rabeprazole 20 mg qd for 7 weeks.
- The incidence and severity of acid-related symptoms with GerdQ [ Time Frame: 2 weeks after PPI ]To compare the incidence and severity of acid-related symptoms after discontinuation of proton-pump inhibitor between reflux patients with and without H. pylori infection
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01249482
|Contact: Yi-Chia Lee, MD,PhD||886-2-23123456 ext firstname.lastname@example.org|
|National Taiwan University Hospital||Recruiting|
|Taipei, Taiwan, 100|
|Principal Investigator:||Yi-Chia Lee, MD,PhD||National Taiwan University Hospital|